诺和平Roadshow 平衡之美美化.pptVIP

2011AACE指南: 糖尿病综合管理治疗目标 35 (完成试验的为29人)名采用基础胰岛素治疗的T2D患者 随机采用detemir或glargine晚上8点注射一次治疗一周，然后在下一周采用另一种胰岛素治疗 在滴定期，根据前一天的CGM的资料来调节每日基础胰岛素的剂量，以便在基础时间 （2400 – 0600 hours）内血糖保持在 70-120 mg/dl .No food was to be eaten from 6 PM until breakfast the next morning (~7 AM) in order to obtain accurate basal BG readings. During both weeks, subjects wore a CGMS (Medtronic CGMS System Gold) until basal BG targets were achieved. Type of basal insulin prior to the study was NPH (1 subject), insulin glargine (13 subjects), and insulin detemir (15 subjects). Evening was defined as the interval from I hour before the last meal until bedtime. Speaker notes In this study, a continuous glucose-monitoring system was used to evaluate the time–action profile of both basal insulin analogues in patients with type 2 diabetes. This is an alternative approach to using a clamp study, and here again we can see a similar profile for both insulins throughout the day. Final mean basal insulin dose for detemir was 26.3 units/day and for glargine was 26.6 units/day (P = 0.837). Target basal glycaemic control was achieved in all subjects in a mean of 3.8 days for detemir and 3.5 days for glargine (P = 0.360). For all subjects in a mean 3.65 days. Mean age of the 29 subjects completing the study (15 females and 14 males) was 58.9±11.6 (SD) years. Mean duration of diabetes was 8.4±4.6 years, mean HbA1c was 7.1±0.9%, and mean BMI was 34.9±8.2 kg/m2. Type of basal insulin prior to the study was NPH (1 subject), insulin glargine (13 subjects) and insulin detemir (15 subjects). 35 (完成试验的为29人)名采用基础胰岛素治疗的T2D患者 随机采用detemir或glargine晚上8点注射一次治疗一周，然后在下一周采用另一种胰岛素治疗 在滴定期，根据前一天的CGM的资料来调节每日基础胰岛素的剂量，以便在基础时间 （2400 – 0600 hours）内血糖保持在 70-120 mg/dl .No food was to be eaten from 6 PM until breakfast the next morning (~7 AM) in order to obtain accurate basal BG readings. During both weeks, subjects wore a CGMS (Medtronic CGMS System Gold) until basal BG targets were achieved. Type of basal insulin prior to the study was